{
    "root": "6d23c13f-f81d-4bc9-9ded-be94c025e8f7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "IVABRADINE",
    "value": "20250221",
    "ingredients": [
        {
            "name": "IVABRADINE HYDROCHLORIDE",
            "code": "TP19837BZK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 )",
    "contraindications": "Adult patients ●     Starting dose is 2.5 (vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. ( 2.1 )",
    "warningsAndPrecautions": "Ivabradine tablets 5 mg tablets are formulated as Light salmon-colored, Capsule-shaped, film-coated scored tablets debossed with \"I5\" divided by the score on one side and plain on the other. \n                  They are supplied as follows:\n                  \n                     Bottles of 60 tablets with child-resistant closure, (NDC 50742-362-60)\n                     Bottles of 180 tablets with child-resistant closure, (NDC 50742-362-18)\n                  \n                  Ivabradine tablets 7.5 mg tablets are formulated as Light salmon-colored, Round-shaped, film-coated tablets debossed with \"I\" on one side and \"7.5\" on the other side. They are supplied as follows:\n                  \n                     Bottles of 60 tablets with child-resistant closure, (NDC 50742-363-60)\n                     Bottles of 180 tablets with child-resistant closure, (NDC 50742-363-18)\n                  \n                  \n                     Storage\n                  \n                  Store ivabradine tablets at 25ºC (77ºF); excursions permitted to 15ºC - 30ºC (59ºF -86ºF) [see USP Controlled Room Temperature].",
    "adverseReactions": "Ivabradine tablets are contraindicated in patients with:\n                  \n                     Acute decompensated heart failure\n                     Clinically significant hypotension\n                     Sick sinus syndrome, sinoatrial block or 3rddegree AV block, unless a functioning demand pacemaker is present\n                     Clinically significant bradycardia [see Warnings and Precautions (5.3)]\n                     \n                     Severe hepatic impairment [see Use in Specific Populations (8.6)]\n                     \n                     Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)]\n                     \n                     Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)]"
}